However, selective depletion of YTHDF2 inhibits the self-renewal capacity of leukemic cells and promotes cell-differentiation and apoptosis, suggesting the therapeutic value of YTHDF2 in controlling AML progression. The gene discussed is YTHDF2; the disease is acute myeloid leukemia.